LYTIX BIOPHARMA
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer therapeutics.
LYTIX BIOPHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Tromsø, Troms, Norway
Country:
Norway
Website Url:
http://www.lytixbiopharma.com
Total Employee:
11+
Status:
Active
Contact:
+47 77 67 55 00
Email Addresses:
[email protected]
Total Funding:
10.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
EctoPharma
EctoPharma is virtual pharmaceutical company focused on commercialising patented technologies by developing new medicines.
Fagron SA
Fagron is a pharmaceutical company specializing in chemicals, equipment, and supplies solutions.
Taiho Oncology
Taiho Oncology is a pharmaceutical company that specializes in developing innovative cancer treatments.
URL Pharma, Inc.
URL Pharma is a pharmaceuticals company specializing in drug research and development services.
Current Advisors List
Current Employees Featured
Founder
Investors List
Picasso Kapital
Picasso Kapital investment in Venture Round - Lytix Biopharma
John Sigurd Svendsen
John Sigurd Svendsen investment in Venture Round - Lytix Biopharma
Norinnova Forvaltning
Norinnova Forvaltning investment in Venture Round - Lytix Biopharma
Sparebanken Nord-Norge
Sparebanken Nord-Norge investment in Venture Round - Lytix Biopharma
Oystein Rekdal
Oystein Rekdal investment in Venture Round - Lytix Biopharma
Såkorn Invest Nord
Såkorn Invest Nord investment in Venture Round - Lytix Biopharma
Norinnova Invest
Norinnova Invest investment in Venture Round - Lytix Biopharma
Newest Events participated
Participated in ICI Boston 2017
on 2017-03-14 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-05 | Lytix Biopharma appoints Stephen Worsley as Chief Business Officer |
Official Site Inspections
http://www.lytixbiopharma.com Semrush global rank: 8.84 M Semrush visits lastest month: 243
- Host name: s20998836.onlinehome-server.info
- IP address: 217.160.183.146
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Lytix Biopharma"
Home - Lytix Biopharma
Aug 16, 2024 · Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon …See details»
About us - Lytix Biopharma
Lytix Biopharma is a clinical-stage biotech company with a highly novel technology platform using host-defense peptide-derived molecules to kill cancer cells and kick start the immune system. …See details»
Overview - Lytix Biopharma
Lytix Biopharma is a clinical-stage biotech company with a highly novel technology platform using host-defense peptide-derived molecules to kill cancer cells and kick start the immune system. …See details»
Lytix Biopharma - Crunchbase Company Profile & Funding
View contacts for Lytix Biopharma to access new leads and connect with decision-makers. Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and …See details»
Lytix Biopharma - LinkedIn
Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s …See details»
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class …
Aug 11, 2020 · LTX-315 is a first-in-class oncolytic peptide that is injected directly into a tumor to induce immunogenic cell death. The compound has demonstrated positive tumor-specific …See details»
Lytix Biopharma: Annual Report for 2022 - PR Newswire
OSLO, Norway, March 30, 2023 /PRNewswire/ -- Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has published its …See details»
Lytix Biopharma - Company Profile & Staff Directory - ContactOut
Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s …See details»
Lytix Biopharma AS - VentureRadar
Lytix Biopharma AS is a privately-owned pharmaceutical company developing novel antimicrobial peptide-based drugs for the treatment of resistant bacterial and fungal infections, as well as …See details»
Lytix Biopharma - Update from licensing partner Verrica …
Nov 5, 2024 · Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived …See details»
Annual Report 2019 - Lytix Biopharma
Personnel and organization Lytix Biopharma’s senior management team at year -end consists of Øystein Rekdal, Chief Executive Officer, Baldur Sveinbjø rnsson, Chief Scientific Officer, and …See details»
Lytix Biopharma Company Profile | Management and Employees …
Www.lytixbiopharma.com Lytix Biopharma Profile and History Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an …See details»
Lytix Biopharma Q3 2024: Positive clinical results and strategic ...
Nov 19, 2024 · Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its …See details»
Lytix Biopharma - Craft
Oct 29, 2024 · Lytix Biopharma is a clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer.See details»
Lytix Biopharma receives milestone payment from Verrica …
Apr 5, 2022 · Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at …See details»
Technology - Lytix Biopharma
Lytix Biopharma has developed a first-in-class 9-mer peptide, LTX-315, modified from the natural host-defense peptide lactoferricin.See details»
Lytix Biopharma: Second quarter and first half of 2022 results
Aug 25, 2022 · Based in Oslo, Norway, Lytix is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's …See details»
Lytix Biopharma AS (LYTIX.OL) - Yahoo Finance
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule …See details»
Lytix Biopharma-动脉网 - vbdata.cn
Lytix Biopharma是一家私人临床阶段生物技术公司，从事抗微生物和癌症治疗的制药公司，致力于开发专有的溶瘤肽作为抗癌的新型免疫疗法。铅化合物LTX-315通过使用患者自身的肿瘤作为 …See details»
Press Releases - Lytix Biopharma
Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion. Read …See details»